463 results
P
Hepatocellular carcinomas (HCCs), non-HCC malignancies
I/C
Contrast-enhanced ultrasound (CEUS) Liver Imaging Reporting and Data System category M (LR-M), CEUS LR-M category, Non-HCC malignancies
O
Proportion of CEUS LR-M in HCC and non-HCC malignancies, Frequency of individual CEUS LR-M imaging features
P
patients with liver lesions
I/C
LI-RADS algorithm, original studies reporting probability of LR-M for HCC and non-HCC malignancy on MRI
O
pooled percentages of HCC and non-HCC malignancy for LR-M, sources of heterogeneity between reported results
P
patients admitted to urban teaching vs nonteaching hospitals
I/C
admission at the beginning vs end of the academic year, July Effect studies
O
mortality, major morbidity, readmission
P
rodents
I/C
unmodified MSC(M), controls
O
mortality rate
P
HIV-infected adults with tuberculosis
I/C
Mycobacterium tuberculosis bloodstream infection (BSI), Patients with HIV-associated tuberculosis but without M. tuberculosis BSI
O
Mortality within 30 days
P
26 studies
I/C
traffic-related metrics, per 500 m decrease in the distance to roads
O
change in small for gestational age
P
young adults
I/C
life events, including becoming a parent, prospective pre-pregnancy/parenthood and post-delivery outcome
O
body mass index (BMI; kg/m^2)
P
patients with recurrent or metastatic head and neck squamous cell carcinomas (R/M HNSCC)
I/C
PD-1/PDL-1 inhibitors, anti-EGFR agents, cetuximab, panitumumab, control, platinum-resistant disease, methotrexate, platinum-based regimens
O
overall survival (OS), progression-free survival (PFS), overall response rates (ORR)
P
patients with M. chimaera infection and a prior history of cardiac surgery
I/C
surgical aortic valve replacement or combined aortic valve and root replacement, lethal events
O
better survival
P
patients with eGFR <60 ml/min/1.73 m
I/C
SGLT2 inhibitors, placebo
O
safety outcomes